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cdentifying prognostic markers is of increasing importance
n patients with congestive heart failure of either ischemic or
onischemic etiology. In nonischemic cardiomyopathies,
he benefits of implantable cardioverter-defibrillators (1)
nd biventricular pacemakers (2) are well documented.
hese therapies have been shown to be cost-effective by
odern standards (3,4) but represent an ever-increasing cost
urden to the health care system. Therefore, identifying
atients who would benefit most from these important
herapies is an imperative (5).
See page 1977
The initial development of the technique of late gadolin-
um enhancement (LGE) in cardiac magnetic resonance
CMR) was to identify necrosis caused by myocardial
nfarction (6,7). However, all that enhances is not infarc-
ion. Late gadolinium enhancement is a marker of myocar-
ial fibrosis of any etiology, and recent studies have docu-
ented its utility in nonischemic cardiomyopathies (8). For
xample, LGE has been shown in acute myocarditis, espe-
ially noted in the basal lateral wall in the midwall and
picardium (9). Patients with hypertrophic cardiomyopathy
ay have LGE, particularly at the right ventricular (RV)
nsertion sites (10), a common location of interstitial fibrosis
n pathological studies. The presence of LGE correlates
ith wall thickness in this disorder. Infiltrative cardiomy-
pathies such as amyloidosis (11) and sarcoidosis (12) may
e identified by LGE, the former often by diffuse subendo-
ardial enhancement and the latter by more focal enhance-
ent that may be reduced by steroid therapy. Other
ardiomyopathies that can show LGE include the RV in
rrhythmogenic RV cardiomyopathy (13) and areas of scar
n Chagas disease (14).
Over the past few years, the group at the Royal Brompton
ospital in London has studied and followed up a cohort of
atients with chronic congestive heart failure with LGE
*Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.
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upported by NIH, NHLBI, RO1 HL075792.MR. They initially showed that LGE is present in
atients with known ischemic cardiomyopathy but also is
resent in patients with nonischemic cardiomyopathy, some
n an infarct distribution (subendocardial progressing to
ransmural), but others in the midwall (15). This group then
ollowed up 101 of the patients with nonischemic cardio-
yopathy over nearly 2 years (16). Thirty-five percent of
hese 101 patients showed midwall fibrosis and had a higher
ncidence of a predefined primary composite end point of
ll-cause mortality and cardiovascular hospitalization than
hose without midwall fibrosis. Mortality alone was similar
etween groups. When corrected for between-group differ-
nces including LV size and function in a multivariate
nalysis, midwall LGE was the only significant predictor of
he primary end point. In addition, the presence of midwall
brosis predicted a higher risk of a secondary end point of
udden cardiac death and ventricular tachycardia.
The work of Assumoll et al. (16) in this issue of the
ournal should be viewed as preliminary and as fodder for
urther study. The sample size was relatively small for an
utcome study, hence the lack of significance in mortality
nd the requirement for composite end points. We do not
now the prognostic implications of the LGE in an infarct
attern in patients without obstructive coronary disease
ecause these were excluded from this particular outcome
tudy. Further multicenter outcome studies of LGE will be
mportant to define the ultimate utility of CMR in both
onischemic and ischemic cardiomyopathies. Patients with
acemakers and defibrillators are still contraindicated from
ndergoing CMR, a growing limitation in congestive heart
ailure. However, safety is being actively examined (17) and
R-compatible devices are in active development by device
anufacturers. It may be that CMR has its most important
ole in defining which patients will benefit most from a
evice, although more study is needed.
The present study adds to our growing understanding of
he prognostic importance of LGE in myocardial disease.
ate gadolinium enhancement was recently shown to be the
ost important independent predictor of major cardiac adverse
vents over other clinical predictors, including ejection fraction
EF), in a cohort of 195 patients who underwent CMR for
linical reasons primarily to evaluate for ischemia in the
etting of coronary artery disease (18). Even the smallest
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November 21, 2006:1986–7 Editorial Commentmount of LGE was predictive of an adverse outcome with
o gradation by the amount of LGE. In contrast, in
onischemic cardiomyopathy in the study of Assomull et al.
16), receiver-operating characteristic analysis showed that
ore than 4.8% of LV mass with LGE differentiated
atients with worse outcomes.
Thus, in both ischemic and nonischemic myocardial
isease, fibrosis is a marker of poor outcome over and above
tandard clinical markers, including EF. Why might this
e? In ischemic cardiomyopathies, it is likely a marker of the
urden of coronary artery disease and its activity. The extent
f infarct scar by CMR is also a better marker of inducible
entricular tachycardia than is EF (19). Although fibrosis is
hallmark of ischemic cardiomyopathies, a recent postmor-
em study shows that extracellular matrix proteins, including
ypes 1, III, and IV collagen, laminin, and fibrinonectin, are
xpressed more frequently in human hearts with dilated
ardiomyopathy than those with ischemic cardiomyopathy
20). Thus, fibrosis is more characteristic of nonischemic
ardiomyopathies. In nonischemic cardiomyopathies, fibro-
is is thought to be at the root of myocardial re-entry leading
o ventricular tachycardia (21). This is especially true in the
picardium based on electrophysiological mapping studies
22). Prior studies using late gadolinium enhancement have
hown that scar that subtends 25% to 75% of the wall thickness
dentifies patients that are at higher risk for inducible ventric-
lar tachycardia on electrophysiological testing (23). Fibrosis
ay also involve the conduction system and lead to dyssyn-
hrony and worsening congestive heart failure.
Risk stratification in patients with congestive heart failure
s a growing necessity in cardiology. It is becoming increas-
ngly apparent that fibrosis may be an important prognostic
arker and may identify patients at higher risk of ventric-
lar arrhythmias and cardiac death. A coalescence of the
bility to image fibrosis by late gadolinium-enhanced CMR
ith an enhanced understanding of its etiology and prog-
ostic implications will advance care of the patient with
ongestive heart failure in the years to come.
eprint requests and correspondence: Dr. Christopher M.
ramer, University of Virginia Health System, Departments of
edicine and Radiology, Lee Street, Box 800170, Charlottesville,
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